20 July, 2019 10:12 CET

EGeen International has been awarded a full services CRO contract by Cyxone of Sweden to conduct its’ upcoming clinical Phase IIb trial for the RA drug candidate Rabeximod. The multi-center Phase IIb trial is expected to begin patient recruitment in the first half of 2020. Cyxone, a Swedish biotech firm focusing on autoimmune diseases, recently submitted an application to the Central Ethics Committee (CEC) in Poland for permission to begin the clinical Phase IIb trial with Rabeximod.